188 related articles for article (PubMed ID: 21718648)
1. [Serum autoantibodies profiling and early-stage cancer detection].
Desmetz C; Lacombe J; Mange A; Maudelonde T; Solassol J
Med Sci (Paris); 2011; 27(6-7):633-8. PubMed ID: 21718648
[TBL] [Abstract][Full Text] [Related]
2. A multiparametric serum marker panel as a complementary test to mammography for the diagnosis of node-negative early-stage breast cancer and DCIS in young women.
Lacombe J; Mangé A; Bougnoux AC; Prassas I; Solassol J
Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1834-42. PubMed ID: 24957886
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies in breast cancer: their use as an aid to early diagnosis.
Chapman C; Murray A; Chakrabarti J; Thorpe A; Woolston C; Sahin U; Barnes A; Robertson J
Ann Oncol; 2007 May; 18(5):868-73. PubMed ID: 17347129
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody profiles as biomarkers of breast cancer.
Tabernero MD; Lv LL; Anderson KS
Cancer Biomark; 2010; 6(5-6):247-56. PubMed ID: 20938085
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody signatures: progress and perspectives for early cancer detection.
Desmetz C; Mange A; Maudelonde T; Solassol J
J Cell Mol Med; 2011 Oct; 15(10):2013-24. PubMed ID: 21651719
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of proteomic strategies to identify antibodies resulting from the humoral immune response to cancer].
Desmetz C; Mangé A; Solassol J
Med Sci (Paris); 2008 Dec; 24(12):1071-6. PubMed ID: 19116117
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies: Opportunities for Early Cancer Detection.
Macdonald IK; Parsy-Kowalska CB; Chapman CJ
Trends Cancer; 2017 Mar; 3(3):198-213. PubMed ID: 28718432
[TBL] [Abstract][Full Text] [Related]
9. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.
Tomkiel JE; Alansari H; Tang N; Virgin JB; Yang X; VandeVord P; Karvonen RL; Granda JL; Kraut MJ; Ensley JF; Fernández-Madrid F
Clin Cancer Res; 2002 Mar; 8(3):752-8. PubMed ID: 11895905
[TBL] [Abstract][Full Text] [Related]
10. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
[TBL] [Abstract][Full Text] [Related]
11. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.
Brichory FM; Misek DE; Yim AM; Krause MC; Giordano TJ; Beer DG; Hanash SM
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9824-9. PubMed ID: 11504947
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers.
Ummanni R; Duscharla D; Barett C; Venz S; Schlomm T; Heinzer H; Walther R; Bokemeyer C; Brümmendorf TH; Murthy PV; Balabanov S
J Proteomics; 2015 Apr; 119():218-29. PubMed ID: 25724726
[TBL] [Abstract][Full Text] [Related]
13. Alpha 2HS-glycoprotein, a tumor-associated antigen (TAA) detected in Mexican patients with early-stage breast cancer.
Fernández-Grijalva AL; Aguilar-Lemarroy A; Jave-Suarez LF; Gutiérrez-Ortega A; Godinez-Melgoza PA; Herrera-Rodríguez SE; Mariscal-Ramírez I; Martínez-Velázquez M; Gawinowicz MA; Martínez-Silva MG; Cruz-Ramos JA; Hernández-Gutiérrez R
J Proteomics; 2015 Jan; 112():301-12. PubMed ID: 25106788
[TBL] [Abstract][Full Text] [Related]
14. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
[TBL] [Abstract][Full Text] [Related]
15. Identifying autoantibody signatures in cancer: a promising challenge.
Desmetz C; Maudelonde T; Mangé A; Solassol J
Expert Rev Proteomics; 2009 Aug; 6(4):377-86. PubMed ID: 19681673
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated autoantibodies as diagnostic and prognostic biomarkers.
Heo CK; Bahk YY; Cho EW
BMB Rep; 2012 Dec; 45(12):677-85. PubMed ID: 23261052
[TBL] [Abstract][Full Text] [Related]
17. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of autoantibody detection in lung cancer.
Solassol J; Maudelonde T; Mange A; Pujol JL
J Thorac Oncol; 2011 May; 6(5):955-62. PubMed ID: 21415775
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma.
Li Y; Li CQ; Guo SJ; Guo W; Jiang HW; Li HC; Tao SC
EBioMedicine; 2020 Mar; 53():102674. PubMed ID: 32113159
[TBL] [Abstract][Full Text] [Related]
20. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
